I think we can all agree it’s in everyone’s best interest to have access to effective antibiotics for people and for animals. It’s critical for public health — and vital for livestock production and well-being.
That’s why it’s also important for those of us in animal agriculture to demonstrate we’re doing our part to protect antibiotic effectiveness and in doing so, help maintain confidence in food safety. In pursuit of those objectives, labels of certain classes of antibiotics — those used in both animals and people — will be transitioning.
In 2012, the U.S. Food and Drug Administration (FDA) put forth plans to change the way feed- and water-based antimicrobials are used in cattle and other production animals. Three documents provide the details: Guidance for Industry No. 209, Guidance for Industry No. 213 and Veterinary Feed Directive (VFD) 21 CFR 558.
The first one (No. 209) is the “what” component. It establishes the key principles: The use of medically important antimicrobial drugs in food-producing animals should be limited to:
- Uses necessary for assuring animal health
- Uses that include veterinary oversight
The second report (No. 213) is the “how” component. It provides a road map for implementing those two principles by addressing issues such as product labeling.
The third report (CFR 558) aims to modernize the VFD process. It’s an effort to streamline procedures while providing greater oversight.
The FDA is taking these steps to protect public health. On that front, it’s the right policy for the right reasons. The FDA calls antimicrobial resistance “a mounting public health problem of global significance.” The FDA fears that if certain antimicrobials are overused in animals, they’ll become less effective in humans.
When the FDA released these reports, the agency said it was pursuing a “voluntary approach” for compliance. The FDA plans to evaluate progress three years after final publication and “consider further actions as warranted.” Guidance for Industry No. 213 was finalized in December 2013. Now the clock is ticking.
From an industry perspective this might not seem ideal. However, it’s preferable to many alternatives, such as elimination of medications or Congressional oversight. No one wants those, either. These steps also go a long way toward protecting long-term access to antibiotics.
The voluntary approach was wise for all parties. It gives everyone time to understand the policies, figure out how to comply with them and determine the most efficient process for transitions.